• Sales of Reflex, Sycrest and Bilanoa
JPY 29.9 billion, up 39% YoY
• Maximize Reflex sales
Utilize the results of post-marketing clinical trials and other evidences
• Grow sales of Sycrest and Bilanoa significantly
Approved long-term prescriptions in 2nd year of sales
Receiving high evaluations for the drugs
Strengthen MR promotions
• Sales of generics: JPY 48.3 billion, up 14% YoY, details on the next slide
• Growing steadily based on local currency
• Expand sales in ASEAN region
• Expand contracted manufacturing business
Japan
• Sales of Reflex, Sycrest and Bilanoa
JPY 29.9 billion, up 39% YoY
• Maximize Reflex sales
Utilize the results of post-marketing clinical trials and other evidences
• Grow sales of Sycrest and Bilanoa significantly
Approved long-term prescriptions in 2nd year of sales
Receiving high evaluations for the drugs
Strengthen MR promotions
• Sales of generics: JPY 48.3 billion, up 14% YoY, details on the next slide
InternationalContribute to income further
• Growing steadily based on local currency
• Expand sales in ASEAN region
• Expand contracted manufacturing business